Clinical Trial Update: Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion [Phase 3]

View source ↗

Summary

Phase 3 trial updates efficacy and safety of ranibizumab in Japanese patients with retinal vein occlusion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Vein Occlusion

Drugs mentioned

• Ranibizumab (Lucentis) (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Retinal Vein Occlusion | Phase 3 | Status: COMPLETED